COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Aug 13, 2024
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024
Company ended the quarter with US$27.8 million in cash
Read more at globenewswire.com
